H. Lundbeck Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Charl van Zyl

Algemeen directeur

DKK 39.6m

Totale compensatie

Percentage CEO-salaris	6.8%
Dienstverband CEO	1.2yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Charl van Zyl's beloning veranderd ten opzichte van H. Lundbeck's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	DKK 3b
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Compensatie versus markt: De totale vergoeding ($USD 5.56M ) Charl } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Danish markt ($USD 3.20M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Charl te vergelijken met de prestaties van het bedrijf.

CEO

Charl van Zyl (57 yo)

1.2yrs

Tenure

DKK 39,600,000

Compensatie

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Charl van Zyl	President & CEO	1.2yrs	DKK 39.60m	geen gegevens
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.3yrs	DKK 10.90m	0.0023% DKK 973.2k
Lars Bang	Executive Vice President of Product Development & Supply	5.8yrs	DKK 10.10m	0.038% DKK 16.4m
Per Luthman	Executive Vice President of Research & Development	5.8yrs	DKK 11.30m	0.014% DKK 6.0m
Tarek Samad	Senior VP & Head of Research	3.5yrs	geen gegevens	geen gegevens
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	geen gegevens	geen gegevens
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	geen gegevens	geen gegevens
Dianne Holto	Executive Vice President of People & Culture	less than a year	geen gegevens	geen gegevens
Ole Chrintz	Senior Vice President of International Markets	no data	geen gegevens	geen gegevens
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.8yrs	geen gegevens	geen gegevens
Bjorn Mogensen	Senior Vice President of Group Finance	2.3yrs	geen gegevens	geen gegevens
Jose Molinuevo	VP & Head of Experimental Medicine	no data	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HLUN A wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lars Rasmussen	Independent Chairman	11.8yrs	DKK 1.70m	0.010% DKK 4.3m
Lene Skole-Sorensen	Deputy Chairman	9.8yrs	DKK 1.20m	0.0062% DKK 2.6m
Jeffrey Berkowitz	Independent Director	6.7yrs	DKK 1.20m	geen gegevens
Lars Holmqvist	Director	9.8yrs	DKK 600.00k	0.0076% DKK 3.2m
Jakob Riis	Director	1.7yrs	DKK 450.00k	0.0055% DKK 2.3m
Ilse Wenzel	Independent Director	3.7yrs	DKK 70.00k	geen gegevens
Santiago Arroyo	Independent Director	3.7yrs	DKK 1.00m	geen gegevens
Camilla Andersson	Employee Representative Director	2.7yrs	DKK 400.00k	0.00010% DKK 42.9k
Dorte Clausen	Employee Representative Director	2.7yrs	DKK 400.00k	0.00011% DKK 47.2k
Hossein Armandi	Employee Representative Director	2.7yrs	DKK 400.00k	geen gegevens
Lasse Skibsbye	Employee Representative Director	2.7yrs	DKK 400.00k	geen gegevens

3.7yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HLUN A wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

H. Lundbeck Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S Appoints Charl Van Zyl as New President

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Take Care Before Diving Into The Deep End On H. Lundbeck A/S (CPH:HLUN A)

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

First quarter 2023 earnings released: EPS: kr.0.89 (vs kr.0.41 in 1Q 2022)

Full year 2022 earnings: Revenues in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for 2022

Investor sentiment improves as stock rises 15%

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck's (CPH:HLUN A) Soft Earnings Are Actually Better Than They Appear

Less than half of directors are independent

Third quarter 2022 earnings released

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

Second quarter 2022 earnings released: EPS: kr.0.51 (vs kr.1.90 in 2Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

Getting In Cheap On H. Lundbeck A/S (CPH:HLUN A) Is Unlikely

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd